CC Chemokine Receptor Type 5 Market Report 2026

The cc chemokine receptor type 5 market size has grown rapidly in recent years. It will grow from $1.54 billion in 2025 to $1.7 billion in 2026 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to discovery of ccr5 role in hiv infection, early development of ccr5 inhibitors, expansion of immunology research programs, clinical trials in inflammatory diseases, growth of targeted receptor therapies.

The cc chemokine receptor type 5 market size is expected to see strong growth in the next few years. It will grow to $2.48 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expansion of personalized immunotherapies, increasing hiv treatment innovation, rising oncology drug development pipelines, growing investment in immune modulation research, advancements in targeted receptor drug design. Major trends in the forecast period include increasing development of ccr5 antagonist therapies, rising focus on hiv and immunology research, expansion of ccr5 applications in oncology, growing adoption of targeted immune modulation, enhanced emphasis on precision drug development.

The rising prevalence of chronic diseases is expected to drive the growth of the CC chemokine receptor type 5 market in the coming years. Chronic diseases are long-term health conditions, such as heart disease, diabetes, and arthritis, that develop gradually and often require continuous management. The incidence of chronic diseases is increasing due to aging populations and the growing prevalence of lifestyle-related risk factors, including poor diet, physical inactivity, and obesity. CC Chemokine Receptor Type 5 (CCR5) plays a significant role in chronic diseases such as human immunodeficiency virus (HIV), functioning as a coreceptor that enables the virus to enter and infect immune cells, thereby contributing to disease progression. For example, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a U.S.-based federal agency, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition in 2023. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Consequently, the growing prevalence of chronic diseases is fueling the expansion of the CC chemokine receptor type 5 market.

The increasing prevalence of HIV is expected to drive the growth of the CC chemokine receptor type 5 market in the coming years. HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, reducing the body’s ability to fight infections and diseases. The rise in HIV cases is primarily due to unsafe sexual practices, which facilitate the virus's transmission between individuals. CC Chemokine Receptor Type 5 (CCR5) assists HIV by serving as a co-receptor that the virus uses, along with CD4, to enter and infect immune cells, promoting viral replication. For example, in October 2025, the Minority HIV/AIDS Fund (MHAF), a US-based government agency, reported that approximately 39.9 million people worldwide were living with HIV in 2023, including 38.6 million adults and 1.4 million children, compared to previous years. Consequently, the rising prevalence of HIV is fueling the growth of the CC chemokine receptor type 5 market.

Major companies in the CC chemokine receptor type 5 market are concentrating on developing new drugs, such as a CCR5 antagonist, to achieve a competitive edge. A CC chemokine receptor type 5 (CCR5) antagonist is a drug that blocks the CC chemokine receptor type 5 (CCR5) on immune cells, preventing certain pathogens, including HIV, from attaching to and entering these cells, thereby inhibiting infection and regulating immune responses. For example, in February 2024, CytoDyn Inc., a US-based biotechnology firm, announced that the U.S. Food and Drug Administration (FDA) had lifted the clinical hold on leronlimab. The company is now permitted to proceed with its planned HIV clinical trial to study leronlimab's effects on chronic inflammation. Leronlimab, a CCR5 antagonist (also called PRO 140), holds potential for multiple therapeutic applications and is being evaluated for various conditions, including HIV and cancer.

Major companies operating in the cc chemokine receptor type 5 market are Cytodyn Inc., Gilead Sciences Inc., ViiV Healthcare Limited, Pfizer Inc., Bristol Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, AbbVie Inc., AstraZeneca plc, Novartis AG, Sanofi SA, Johnson & Johnson, Amgen Inc., Boehringer Ingelheim International GmbH, F Hoffmann-La Roche Ltd, Ono Pharmaceutical Co Ltd, Avexa Limited, Incyte Corporation, Humanigen Inc., Biogen Inc.

North America was the largest region in the CC chemokine receptor type 5 market in 2025. The regions covered in the cc chemokine receptor type 5 market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cc chemokine receptor type 5 market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cc chemokine receptor type 5 market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing inputs, analytical instruments, and clinical research supplies. Pharmaceutical companies and research institutes in North America and Europe are most affected due to reliance on specialized imported compounds, while Asia-Pacific faces cost pressure in drug development and export. These tariffs are increasing research costs and extending development timelines. However, they are also encouraging domestic drug manufacturing, regional research collaborations, and investment in localized biopharmaceutical production capabilities.

The cc chemokine receptor type 5 market research report is one of a series of new reports that provides cc chemokine receptor type 5 market statistics, including cc chemokine receptor type 5 industry global market size, regional shares, competitors with a cc chemokine receptor type 5 market share, detailed cc chemokine receptor type 5 market segments, market trends and opportunities, and any further data you may need to thrive in the cc chemokine receptor type 5 industry. This cc chemokine receptor type 5 market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

CC chemokine receptor type 5 (CCR5) is a protein found on the surface of white blood cells that plays a crucial role in the immune system by serving as a receptor for specific chemokines, which are signaling molecules that guide immune cells to sites of infection or inflammation. It is implicated in the development of diseases such as HIV, where it functions as a co-receptor, enabling the virus to enter and infect host cells, making it a significant target for therapeutic strategies.

The primary types of CC chemokine receptor type 5 include BMS-813160, AG-1105, CCL-14, DS-001, among others. BMS-813160 is a small-molecule inhibitor developed by Bristol-Myers Squibb that targets specific receptors or pathways and is being investigated for its potential therapeutic benefits in various conditions, including cancer. Distribution occurs through hospitals, clinics, online pharmacies, and retail pharmacies. Applications cover infectious diseases, gastrointestinal disorders, immunology, oncology, and more, and end-users include research institutes, pharmaceutical companies, and healthcare facilities.

The CC chemokine receptor type 5 market consists of sales of receptor antagonists, monoclonal antibodies, small molecule inhibitors, and gene editing therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.